SYH2053 injection

DRUG2 trials

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions

Heterozygous Familial Hypercholesterolemia (HeFH)Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Phase 3

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

RecruitingNCT07421297

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Start: 2026-02-28End: 2028-01-31Target: 760Updated: 2026-04-07

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

RecruitingNCT07465263

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Heterozygous Familial Hypercholesterolemia (HeFH)

Start: 2026-03-31End: 2028-05-31Target: 135Updated: 2026-07-08